Navigation Links
TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer
Date:1/13/2010

SCOTTSDALE, Ariz. Jan. 13, 2010 Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

The study, Tumor MicroRNA Biomarkers Associated with De Novo Chemoresistance in Small Cell Lung Cancer, will be presented today in San Diego at a joint conference of the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC).

This breakthrough is critical since patients with small-cell lung cancer (SCLC) often do not get a second chance at therapies to combat this aggressive type of cancer.

"For patients with small cell lung cancer, there are really only about two chemotherapy options. We need to be more precise with our treatments and identify who is going to be resistant up front in order to design better clinical trials that will identify effective therapies for these at-risk patients," said Dr. Glen J. Weiss, director of Thoracic Oncology at TCRS, who presented the findings at AACR-IASLC's Joint Conference on Molecular Origins of Lung Cancer.

TCRS is a partnership between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare that enables laboratory discoveries to be quickly turned into targeted therapies that can be tested with patients at the Virginia G. Piper Cancer Center in Scottsdale.

Of the nearly 32,000 new cases of SCLC diagnosed in the U.S. every year, between 15 and 30 percent will be chemoresistant to first-line therapy, or about 6,500 SCLC patients annually. SCLC tends to spread much more quickly than non-small cell lung cancer. There are three types of SCLC: small cell carcinoma (oat cell cancer), mixed small cell/large cell carcinoma, and combined small cell carcinoma.

The study led by Dr. Weiss proposed to look at how to best identify those SCLC patients who would be chemoresistant. By profiling tumors, he and a team of TGen researchers identified at least three tumor microRNAs that appear to predict small cell lung cancer patients who will prove resistant to first-line chemotherapy. In addition to researchers at TGen, Dr. Weiss was assisted by scientists at the Scottsdale Clinical Research Institute and the Van Andel Research Institute.

MicroRNAs are small molecules that regulate gene expression in the process of making proteins as well as directing the structure and function of cells. This regulation usually prevents cancer and other diseases.

Weiss and colleagues evaluated 34 patients at with varying stages of SCLC. The median age of the patients was 69.1 years, and half were men. All 34 received systemic chemotherapy. There were two complete responses and 13 partial responses. Two patients had stable disease and four had progressive disease.

Three microRNAs biomarkers were identified as being closely linked with chemoresistance: miR-92a-2*, miR-147, and miR-574-5p. Although 47 percent of the patients presented with hypertension and 32 percent presented with emphysema or chronic obstructive pulmonary disease, neither of these co-morbidities were linked with chemoresistance.

These findings should help clinicians design better drug trials.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. GE Healthcare to evaluate and develop novel imaging technology
2. Scott & White Healthcare researcher finds success with new anti-cancer drug
3. Scott & White Healthcare researcher finds success with new anti-cancer drug
4. GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live
5. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
6. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
7. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
8. Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
9. Hand hygiene initiative aims to decrease healthcare-associated infection in developing countries
10. Conference to examine role technology can play in helping US manage healthcare costs
11. Researchers discover genetic differences between lethal and treatable forms of leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ... BreastSentry™ , a new risk stratification test for breast cancer, ... Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test ... lifetime risk for developing breast cancer.   ... BreastSentry measures the fasting ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Mass spectrometry ... The utilization of this technology is driven by its potential to perform challenging analyses ... are also some challenges that must be addressed for it to be routinely used ...
(Date:3/28/2017)... , March 28, 2017 Summary ... understand Enzo Biochem and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
(Date:3/28/2017)... Dr. Chris Yu , Chief ... Anpac Bio-Medical Science Company , announced this week ... and reporting over 40,000 cases worldwide of the ... liquid biopsy tests. Described as "game ... Anpac Bio,s CDA medical devices and technology effectively ...
Breaking Biology Technology: